Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma

Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Yusri Elsayed(Janssen (United States)), Kodandaram Pillarisetti(Johnson & Johnson (United States)), Brandi Hilder(Sheba Medical Center), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Brett Hanna(Janssen (United States)), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Tong‐Yuan Yang(Johnson & Johnson (United States)), Jennifer Smit(Janssen (United States)), Jeffrey R. Infante(Cancer Research Center), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Shoba Shetty(Janssen (United States)), Qun Jiao(Janssen (United States)), Amarnath Sharma, Homer Adams(Janssen (United States)), Yu‐Nien Sun(Janssen (United States)), Xuewen Ma(Janssen (United States))
Targeted Oncology
August 1, 2022
10.1007/s11523-022-00904-y
Cited by 1

Related Papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
|Science|2007|852
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647